Cymbalta is a prescription medication that contains duloxetine as its sole active ingredient. Duloxetine belongs to the class of serotonin-norepinephrine reuptake inhibitors (SNRIs), which are commonly used to treat mood disorders and certain types of chronic pain. In Hong Kong, Cymbalta is regulated by the Department of Health and is available in pill form at the following strengths: 20 mg, 30 mg, 40 mg, and 60 mg.
Duloxetine inhibits the reuptake of two neurotransmitters-serotonin and norepinephrine-by blocking their respective transporters. This increases the concentration of these chemicals in the synaptic cleft, enhancing signaling pathways that modulate mood, pain perception, and stress responses.
By augmenting serotonergic and noradrenergic activity, duloxetine helps regulate the neural circuits involved in depression, anxiety, and the transmission of pain signals.
These indications are recognised by health authorities in many jurisdictions, including the United States FDA and the European EMA. In Hong Kong, the Department of Health has approved Cymbalta for the same therapeutic categories.
Off-label use requires medical supervision and an individualized risk-benefit assessment.
Absolute contraindications
Known hypersensitivity to duloxetine or any pill excipients.
Current use of monoamine oxidase inhibitors (MAOIs); a wash-out period of at least 14 days is required after stopping an MAOI.
Uncontrolled narrow-angle glaucoma.
Severe hepatic impairment (Child-Pugh C).
Relative contraindications
Moderate hepatic impairment (Child-Pugh B) - dose reduction to 30 mg once daily is advised.
Severe renal impairment (creatinine clearance <30 mL/min) - use is generally discouraged.
Pregnancy (especially first trimester) and breastfeeding - discuss risks versus benefits with a healthcare professional.
History of bipolar disorder - risk of inducing mania.
Special populations
Elderly: May be more susceptible to hyponatremia and falls; start with the lowest effective dose.
Adolescents: Cymbalta is not approved for use under 18 years of age for depressive or anxiety disorders in Hong Kong.
Major interactions
Other serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants, tramadol, linezolid) - increase serotonin syndrome risk.
Strong CYP1A2 or CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) - raise duloxetine plasma levels, potentially intensifying side effects.
Moderate interactions
Non-steroidal anti-inflammatory drugs (NSAIDs) - may elevate bleeding risk.
Anticoagulants (warfarin) - monitor INR closely.
Major Depressive Disorder & Generalised Anxiety Disorder
Initiate 60 mg once daily; may reduce to 30 mg if tolerability is an issue.
Diabetic Peripheral Neuropathic Pain, Fibromyalgia, Chronic Musculoskeletal Pain
Start with 60 mg once daily; for patients with hepatic impairment or who experience significant side effects, a 30 mg dose may be used.
Available strengths - 20 mg, 30 mg, 40 mg, and 60 mg tablets. The 20 mg and 40 mg strengths are typically used for dose titration or when a specific intermediate dose is needed.
This article provides educational information about Cymbalta (duloxetine) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Cymbalta is a prescription medication; you should carry it in its original labelled container along with a copy of the prescription or a doctor's note. In Hong Kong and most destination countries, this documentation satisfies customs requirements for personal use.
Standard workplace drug screens typically test for substances of abuse, not prescription antidepressants. However, some sports organisations may require disclosure of all medications; you should inform the relevant medical officer if a therapeutic use exemption is needed.
Cymbalta tablets are round, film-coated, and come in different colours and imprint codes depending on the dose:
The active ingredient and dosage strengths are consistent worldwide, but inactive excipients (e.g., dyes or binders) may vary slightly to meet local manufacturing regulations. These variations rarely affect efficacy but can be relevant for patients with specific allergies.
Cymbalta (an SNRI) influences both serotonin and norepinephrine pathways, whereas sertraline and fluoxetine (SSRIs) primarily target serotonin. This dual action can be advantageous for patients with concurrent pain conditions, but it may also increase the risk of blood-pressure changes and certain drug interactions.
Most patients notice an improvement in mood within 1-2 weeks, but the full therapeutic effect may take up to 6-8 weeks. Patience and regular follow-up are essential during this period.
Transitioning between SNRIs should be done under medical supervision. Some clinicians recommend a brief overlap or a short taper of the previous drug to minimise discontinuation symptoms, but exact protocols depend on the specific medications involved.
Cymbalta does not contain sulfonamide components. However, if you have a known allergy to any of the inactive ingredients listed on your prescription label, discuss alternatives with your pharmacist.
Moderate alcohol consumption is generally permissible, but excessive intake can increase liver strain and exacerbate drowsiness or dizziness. If you notice intensified side effects after drinking, reduce alcohol intake and consult your physician.
Cymbalta is a brand-name formulation that includes specific proprietary excipients and patent-protected manufacturing processes. Generic duloxetine, when available, may be priced lower due to reduced development costs. Pricing can also vary based on pharmacy markup, insurance coverage, and regional market factors.
